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Nicotinamide mononucleotide adenylyl transferase 2 (NMNAT2) is a key 
neuronal maintenance factor which provides potent neuroprotection 
in several models of neurological disorders. NMNAT2 is significantly re-
duced in Alzheimer’s, Huntington’s, Parkinson’s diseases.  
MicroRNAs have emerged as key regulators of biological processes in 
animals. The microRNA system is part of the cell’s epigenetic arsenal 
that shapes the formation and tight regulation of gene networks during 
the establishment and the remodelling of the brain by controlling both 
levels and translation of messenger RNA. Deregulation of miRNA func-
tion is associated with a plethora of human diseases and they are 
considered a key molecular tool for the diagnosis and prognosis of hu-
man diseases. Up to date, NMNAT2 regulation by microRNAs has not 
been investigated. 
Here we investigate NMNAT2 role in axonal growth of primary cortical 
neurons. Consequently, we identify four putative miRNAs that target 
NMNAT2 and study their effect on axonal growth and NMNAT2 mRNA 
expression. We identify miR-129-3p as a regulator of NMNAT2 in cortical 
neurons as it both limits their axonal length and reduces the mRNA levels 
of NMNAT2. 
Understanding microRNA regulation of NMNAT2 can build a strong mo-
mentum to encourage studies of miRNAs as molecular tools for the di-
agnosis and prognosis of NMNAT2 related pathologies as long as mech-
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Chapter 1: INTRODUCTION 
 
1.1 The neuron: Growth and Development  
Neurons alongside with glial cells, are the basic building blocks of the nervous 
system. The mature brain comprises billions of neurons which can be classi-
fied into at least a thousand different types and even more glial cells 
whereas the precursor of the brain, the neural plate, comprises a few hun-
dred of cells. This significant difference indicates that regulation of the prolif-
eration of nervous cells plays a major role since the beginning of the nervous 
system’s development (Kandel et al., 2013). 
Cognition and behaviour majorly depend on the organisation of neurons in 
complex circuits with precise structure and function rather than on their num-
ber and variety (Kandel et al., 2013). 
The typical neuron has four morphologically defined regions: the cell body, 
dendrites, axon, and presynaptic terminals. The cell body or soma contains 
the nucleus, and the endoplasmic reticulum, where the majority of the cell’s 
proteins are synthesized. The cell body usually projects into two kinds of pro-
cesses, dendrites and axons, which vary vastly in their length, branching pat-
tern, thickness and molecular composition. The neuronal polarisation is a syn-
ergistic process that requires the regulation of gene transcription, the cyto-
skeleton and membrane structure and dynamics (da Silva and Dotti, 2002). 
Dendrites, as their name indicates, sprout like tree branches out of the soma 
and are the main apparatus for receiving signals from other neurons. The 
growing axon extends to some distance from the soma of the neuron and 




grow to the length of 30 metres in blue whales and more than 1 metre in the 
human body in (Goldberg, 2003; Smith, 2009).  
 
 
Figure 1: Different Types of Neurons. A. Purkinje cell B. Granule cell C. Motor neuron D. Tripolar 
neuron E. Pyramidal Cell F. Chandelier cell G. Spindle neuron H. Stelate Cell (Ferris 
Jabr;Based on constructions and drawings by Cajal). 
 
1.1.1 Neuronal Polarisation, an introduction 
Cell polarisation is essential for the development and function of various cell 
types that acquire morphological asymmetry in response to intrinsic and ex-
trinsic cues. Naturally, neurons are among the most highly polarised cells as 




processes (axons and dendrites) to mediate the flow of information through 
the nervous system.   
Cultured primary neurons are very useful for developmental studies because 
they initially do not show morphological signs of polarisation, and they ac-
quire their specialised features gradually. After initial plating, extension of sev-
eral short similar processes occurs and soon, one of these processes is estab-
lished as the axon and the rest of the processes acquire dendritic features 
(Figure 2). 
 
Much of our knowledge on the cellular and molecular mechanisms behind 
neuronal polarization derives from work performed on rodents’ brains and 
cell cultures (Dotti, Sullivan and Banker, 1988; da Silva and Dotti, 2002). Our 
understanding of the molecular mechanisms responsible for mammalian 
neuronal polarisation has been studied predominantly through studies on 
cultured primary hippocampal neurons (Dotti, Sullivan and Banker, 1988; 
Tahirovic and Bradke, 2009). More recent studies have been focusing on the 
roles of extracellular and intracellular signalling molecules on neuronal po-
larisation in vivo, by using electroporation and knock-in and knockout mice 
(Funahashi et al., 2014; Takano et al., 2015).It has been shown that both ex-
tracellular signalling and intrinsic mechanisms modulate the generation and 
maintenance of neuronal polarity. 
A central role in polarisation is provided by cytoskeletal proteins which main-
tain elongated processes and drive growth (da Silva and Dotti, 2002; Lewis, 
Courchet and Polleux, 2013). A destabilisation of the actin filaments in a 
young neurite and cytoskeletal rearrangements are essential steps in driving 









1.1.2 Axon: Growth and Guidance 
An axon is typically a single long process that transmits signals to other neu-
rons by releasing neurotransmitters. Dendrites are composed of multiple 
branched processes and dendritic spines, which contain neurotransmitter 
receptors to receive signals from other neurons. The formation and mainte-
nance of such distinct cellular compartments are essential for the proper de-
velopment and physiology of the nervous system.  
The axonal growth and guidance require a precisely choreographed se-
quence of events in the nervous system. Firstly, neurons and their surrounding 
target tissues must be specified in expressing the correct nexus of receptors 
and guidance cues respectively (Lewis, Courchet and Polleux, 2013). Sec-
ondly, receptors must be assembled into the correct complexes and local-
ised to the axonal or dendritic growth cones, while guidance cues must be 
correctly shipped to and localised within the extracellular environment.  
Lastly, signaling mechanisms must be in place to integrate and propagate 
signals from the surface receptors into alterations in the growth cone actin 
Figure 2: Four stages in the in vitro polarisation of a neuron. A. Lamellipodia For-
mation (Shortly after plating) B. Neurite Formation(0.5-1.5 days) C. One neurite be-
comes the axon, (1.5-3 days) D. The other neurites become Dendrites (4-7 days) E. 
Maturation (>7 days). Based on an image from Principles of Neural Science, 5th 
edition, McGraw-Hill, 2013 




and tubulin cytoskeleton resulting in steering decisions (Dent and Gertler, 
2003). 
The key neuronal element responsible for axonal growth is a specialized struc-
ture at the tip of the axon called the growth cone. Both axons and dendrites 
use growth cones for elongation, but the axonal ones have been studied 
more extensively. Τhe growth cone is both a sensory structure that receives 
directional cues from the environment as well as a motor structure that drives 
axon elongation (Lowery and Van Vactor, 2009). 
During development, growth cones follow specific pathways and navigate 
through a plethora of decision points to find their correct targets. At each 
point, growth cones face a number of guidance cues in their extracellular 
environments (Dickson, 2002). 
Several families of phylogenetically conserved families of guidance cues 
and receptors have been discovered. These include semaphorins (semas) 
and their plexin (Plex) and neuropilin receptors (Pasterkamp and Kolodkin, 
2003), netrins and their deleted in colorectal carcinoma (DCC) and UNC5 
receptors for netrins (Li et al., 2002), slits and their roundabout (Robo) recep-
tors (Brose and Tessier-Lavigne, 2000) and ephrins and their Eph receptors 
(Kullander and Klein, 2002). 
1.1.3 Axonal Transport 
Axonal transport is an essential process in neurons because of the significant 
geometry, polarity and size of these cells. Anterograde transport supplies dis-
tal axons with newly synthesised proteins and lipids, synaptic components 
required to maintain presynaptic activity and mitochondria for local energy 




removing misfolded, aggregated and aging proteins as well as organelles 
from the distal axon for degradation and recycling of components. Retro-
grade axonal transport is also involved in intracellular transport of distal 
trophic signals to the soma and thus plays a major role in neurotrophic and 
injury response signalling. Until recently, it was broadly believed that the 
axon, which can extend up to metres from the cell body, depended exclu-
sively on the biosynthetic and degradative activities of the soma which high-
lighted the necessity and importance of active transport. Genetic evidence 
though confirms the crucial role for active transport in the neuron as defects 
in many of the proteins involved, such as kinesins and dynein lead to diseases 
that are characterized by axonal degeneration (Blackstone, O’Kane and 







Figure 3: Membrane trafficking in the neu-
ron. 1. Proteins and lipids of secretory orga-
nelles are synthesized in the endoplasmic 
reticulum and transported to the Golgi 
complex, where large dense-core vesicles 
(peptide-containing secretory granules) 
and synaptic vesicle precursors are as-
sembled. 2. Large dense-core vesicles 
and transport vesicles that carry synaptic 
vesicle proteins travel down the axon via 
axonal transport. 3. At the nerve terminals 
the synaptic vesicles are assembled and 
loaded with nonpeptide neurotransmit-
ters. Synaptic vesicles and large dense-
core vesicles release their contents by ex-
ocytosis. 4. Following exocytosis, large 
dense-core vesicle membranes are re-
turned to the cell body for reuse or degra-
dation. Synaptic vesicle membranes un-
dergo many cycles of local exocytosis 
and endocytosis in the presynaptic termi-
nal. Edited from Principles of Neural Sci-




1.1.4 Local Translation  
RNA localisation and localised translation are conserved mechanisms of spa-
tiotemporal control of protein expression. This could prove especially im-
portant for highly polarised and morphologically complex cells such as neu-
rons (Zappulo et al., 2017) in which local translation allows axons and den-
drites to remodel their proteome precisely in response to local demand. 
Cell-cell signalling depends on the cell’s ability to adjust their local proteome 
with spatiotemporal precision in response to extracellular signals. Many 
mRNAs present specific subcellular localisation patterns in mammals (Mili, 
Moissoglu and Macara, 2008) as well as in  Drosophila melanogaster(Lécuyer 
et al., 2007), which implies that local mRNA translation may have a general 
function in regulation of the local proteome.  
Local protein synthesis has several advantages over the transport of pre-ex-
isting proteins from one part of the cell to another (Jung, Yoon and Holt, 2012). To 
begin with, translationally silent forms of mRNAs can be locally stored and 
when needed, be used to make several copies of a protein. Secondly, dur-
ing protein transport, the ectopic presence of proteins in other parts of the 
cell is avoided. Moreover, mRNAs can reach different subcellular compart-
ments using ‘spatial’ information encrypted in their untranslated regions 
(UTRs) without changes in structure and function of the proteins they encode. 
Lastly, there are properties unique to newly produced proteins which may 
provide further signalling information. 
Local mRNA translation has been shown to mediate synaptic plasticity in 
dendritic spines and there are studies that provide valuable insight on the 
underlying mechanisms of regulation of local mRNA synthesis by extrinsic sig-




components of the translation machinery are present in developing and ma-
ture axons and axonal protein synthesis has been shown to be involved in 
several physiological and pathological processes such as amyotrophic lat-
eral sclerosis (ALS), spinal muscular atrophy (SMA) and Alzheimer’s disease 
(AD) (Batista and Hengst, 2016; Spaulding and Burgess, 2017; Costa and 
Willis, 2018). Through axonal RNA-sequencing, thousands of mRNAs have 
been identified (Baleriola et al., 2014; Minis et al., 2014; Kar, Lee and Twiss, 
2018). These vary between neuronal subtypes (Kar, Lee and Twiss, 2018), ax-
onal subdomains and throughout the axon’s lifetime (Zivraj et al., 2010; Gumy 
et al., 2011). A cell-type specific genome-wide analysis of the axonal trans-
latome further elucidated the dynamic nature of local translation during the 
development and maintenance of neuronal wiring in vivo. Through the anal-
ysis there were identified axonally translated mRNAs which encoding func-
tionally linked regulators who show developmental co-regulation (Shigeoka 
et al., 2016). 
The cohabitation of several different mRNAs in the same subcellular com-
partments raises the question of how specific groups of mRNAs are translated 
in response to specific cues. Axon guidance cues along with neurotrophins 
stimulate kinases and release their associated mRNAs for local translation 
(Hörnberg and Holt, 2013). The mRNA specificity of axonal translation may 
require a spatiotemporal combination of signalling pathways. 
It has been suggested that a multiple cue integration can lead in signaling 
cooperation and crosstalk by multiple pathways which can fine-tune local 
translation for particular physiological and developmental situations. 





1.2 microRNAs, tiny but mighty 
1.2.1 miRNA Biogenesis 
The human genome project revealed that protein-coding sequences consti-
tute ~1.5 % of the entire genome and the remaining ~98.5 % of the genome 
contains introns, regulatory DNA sequences, interspersed elements and non-
coding RNA (ncRNA) molecules (Lander et al., 2001).  The majority of mam-
malian genomes are transcribed into ncRNAs, many of which are alterna-
tively spliced or processed into smaller products. To this day, two types of non-
coding RNAs have been identified—short non-coding RNA and long non-
coding RNA molecules (Hüttenhofer, Schattner and Polacek, 2005). The short 
non-coding RNA molecules include microRNA (miRNA), small interfering RNA 
(siRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), piwi-inter-
acting RNA (pi-RNA), transferRNA (tRNA), ribosomal RNA (rRNA) and other 
uncharacterized small molecules (Hüttenhofer, Schattner and Polacek, 2005; 
Kaikkonen, Lam and Glass, 2011). MicroRNAs (miRNAs) are very small (18-23 
nucleotides) yet powerful regulators. They are endogenous, non-coding 
RNAs which mediate significant gene-regulatory events by binding to the 3’ 
untranslated region (3’UTR) of mRNAs of protein-coding genes directing their 
translational repression and/or degradation. The repression of these regula-
tory targets leads to decrease in translational efficiency and/or mRNA levels 
(Guo et al., 2010). MicroRNAs are highly conserved across organisms includ-
ing vertebrates and were first discovered in Caenorhabditis elegans. In 1991, 
Gary Ruvkun’s lab observed that the deletion of two small sequences in the 
3′untranslated region (3′UTR) of the lin-14 mRNA caused lin-14 protein to ac-
cumulate (Wightman et al., 1991). 
 These deletions had no effect in the stability or function of lin-14 protein, sug-




hypothesised that an unidentified regulatory factor binds to these se-
quences and represses the encoded protein’s synthesis. A couple of years 
later, the source of this translational repression was identified as a new class 
of regulatory molecules: microRNAs. In recent years, miRNAs have gathered 
avid scientific interest which is illustrated by the fact that up to date miRbase 
contains 38589 entries potentially representing hairpin precursor miRNAs in 
271 species (Kozomara and Griffiths-Jones, 2014).  
 
As mentioned above, miRNA-binding sites are usually located in the 3′ UTR 
of mRNAs. The domain at the 5′ end of miRNAs that extends from nucleo-
tide position 2 to 7 is essential for target recognition and is termed as the 
“miRNA seed”. The downstream nucleotides of miRNA (principally nucleo-
tide 8 and less importantly nucleotides 13–16) also contribute to binding 
with the target mRNAs (Bartel, 2009a).  
 
In several species, there are multiple miRNA loci with related sequences as a 
result of gene duplication (Hertel et al., 2006; Berezikov, 2011). In most cases 
miRNAs with identical sequences at nucleotides 2-8 of the mature miRNA 
belong to the same miRNA family. For example, the human genome con-
tains 14 paralogous loci that belong to the let-7 family, a highly conserved, 
amongst bilaterian animals, miRNA family that suppresses cell proliferation 
and promotes cell differentiation. Some miRNAs share an evolutionary origin 
but differ in the miRNA seed (Berezikov, 2011; Moran et al., 2017). 
miRNA genes are transcribed by RNA polymerase II (Pol II) producing a long 
primary transcript that has a local hairpin structure where miRNA sequences 
are embedded. Transcription is controlled by RNA Pol II- associated transcrip-
tion factors and epigenetic regulators (CAI, Hagedorn and Cullen, 2004). 




addition some endogenous miRNA-like small RNAs are issued from tRNAs that 
are transcribed from RNA Pol III (Babiarz et al., 2008). miRNA expression has 
been shown to be positively or negatively regulated by transcription factors, 
such as p53, MYC, ZEB2 and MYOD1 (Kim, Han and Siomi, 2009; Krol, Loedige 
and Filipowicz, 2010). There has also been described epigenetic control, 
such as histone modifications and DNA methylation (Davis-Dusenbery and 
Hata, 2010).  
After transcription, the primary miRNA (pri-miRNA) is subjected to maturation. 
pri-miRNA is long (over 1 kb) and contains a local stem-loop structure in 
which mature miRNA sequences are embedded. A pri-miRNA typically com-
prises a stem of 33-35 bp, a terminal loop and single-stranded RNA segments 
at 5’ and 3’ sides. Maturation process is initiated by the nuclear RNase III 
Drosha which crops the stem-stem loop to release a small hairpin-shaped 
RNA of  ~65 nucleotides in length (pre-miRNA)(Lee et al., 2003).  Along with 
its essential cofactor DGCR8, Drosha forms a complex called Microprocessor 
(Denli et al., 2004).  Drosha and DGCR8 are extremely important for cell pro-
liferation and differentiation and are conserved in animals (Filippov et al., 
2000; Wu et al., 2000; Fortin, Nicholson and Nicholson, 2002).  After the Drosha 
processing, pre-mi-miRNA is exported into the cytoplasm by the protein ex-
portin 5 which forms a transport complex with GTP-binding nuclear protein 
RAN.GTP and the pre-miRNA (Yi et al., 2003; Lund et al., 2004). Following 
translocation via the nuclear pore complex, GTP is hydrolysed, the complex 
disassembles and the pre-miRNA is released into the cytosol. Upon export to 
the cytoplasm, Dicer cleaves pre-miRNA near the terminal loop, liberating a 
small RNA duplex consisting a ‘passenger’ and a ‘guide’ strand (Ha and Kim, 
2014). Dicer binds to pre-miRNA with a preference for a two-nucleotide-long 




Following Dicer processing, the RNA duplex is released and subsequently 
loaded onto human and Argonaut protein (AGO 1-4) to form an effector 
complex called RNA-induced silencing complex (RISC) (Hammond et al., 
2001) RISC assembly comprises two steps: the loading of the RNA duplex and 






Figure 4: microRNA biogenesis pathway. microRNAs (miRNAs) are genomically encoded. 
miRNA genes generally have RNA polymerase Pol II promoters, and their transcripts can un-
dergo splicing and polyadenylation. The transcript is referred to as the primary miRNA (pri-
miRNA). This transcript is cleaved in the nucleus by an enzyme complex that contains the 
RNaseIII enzyme Drosha, and the double-stranded RNA binding-domain protein Pasha. The 
product of this cleavage is the precursor miRNA (pre-miRNA), which is exported to the cyto-
plasm by exportin 5. Once in the cytoplasm, the pre-miRNA is cleaved by an enzyme com-
plex that is functionally similar to the nuclear cleavage complex, and comprises the proteins 
Dicer and loquacious. The resulting miRNA duplex is then unwound, (possibly by the helicase 
armitage). The guide strand is translocated to the RNA-induced silencing complex (RISC) 
where it binds to a target mRNA, whereas the passenger strand is destroyed. The cellular 
structure most closely associated with the RISC, and visible at the light microscopic level, is 
the P body. Cytoplasmic destinations of miRNAs include both P bodies and polysomes; how-
ever, exchange between these compartments is speculative. Armitage might also control 
whether or not a miRNA/mRNA duplex is translated (Kosik, 2006).  
 
Consequently, miRNA duplex loading, the pre-RISC (in which AGO proteins 
associate with RNA duplexes) removes the passenger strand to generate a 
mature RISC. RISC loading of small RNA duplexes is an active process that 
requires ATP, whereas the release of the passenger strand is ATP-independ-
ent (Tomari et al., 2004; Kawamata, Seitz and Tomari, 2009; Yoda et al., 2010). 
The guide strand is determined during the AGO loading step, based on the 
relative thermodynamic stability of the two ends of the small RNA duplex 
(Khvorova, Reynolds and Jayasena, 2003; Schwarz et al., 2003). The strand 
with an unstable terminus at the 5’ side is typically selected as the guide 
strand. Another factor that acts as a determinant for strand choice is the first 
nucleotide sequence since AGO proteins select for guide strands with a U at 
nucleotide position 1. Key characteristics of human miRNA guide strands are 




strands have a C-bias at the 5′-end and an excess of pyrimidines (Meijer, 
Smith and Bushell, 2014). Until recently it was considered that the passenger 
strand undergoes quick degradation which results in a strong bias in favour 
of the guide strand in the mature miRNA pool. Although, the strand that is 
not favoured can also get selected and the less abundant passenger strand 
can also have a silencing function although less potently than the more 
abundant guide strand. Arm switching, the phenomenon where the mature 
miRNA switches between one of the two arms of precursor miRNA has been 
observed to occur in different species, tissue types, or development stages 
(Chen et al., 2018). In conclusion, the  miRISC protein complex is composed 
by Argonaut 2 and other regulatory proteins (Fabian and Sonenberg, 2012) 
and allows binding on specific sequences in the 3’UTR of targeted mRNAs. 
 
 
Figure 5: Model for Differential miRNA Strand Selection by AGO1 and AGO2. AGO1 strand 
selection is influenced by 5’uridine in addition to the previously proposed thermodynamic 
rule, while it is insensitive to the positions of central mismatches. In contrast, AGO2 strand 
selection is highly sensitive to 9th and 10th base-pairing status. Edited from (Okamura, Liu 












1.2.2 Mechanisms of miRNA-mRNA interaction and function  
 
The binding of a miRNA to its target mRNA results in repression of protein syn-
thesis by degradation of the transcript or inhibition of protein translation. The 
specificity of interaction is determined by the complementarity between a 
core sequence of ~6-8 nucleotides in the microRNA and their specific seed 
sequence in the target 3’UTR allowing the recognition of multiple mRNAs 3’ 
UTRs by a single microRNA and the downregulation of each mRNA by multi-
ple microRNAs (Bartel, 2009b).   
All nuclear transcribed eukaryotic mRNAs contain a 5′ m7GpppN structure 
(where N is any nucleotide) termed the 5′ cap, which interacts with the eu-
karyotic translation initiation factor eIF4E (reviewed in ref. 4). eIF4E, along with 
other eIFs, in turn recruits ribosomes to initiate mRNA translation (Fabian and 
Sonenberg, 2012). The miRISC has been shown to inhibit cap-dependent 
translation at both initiation (by interfering with ribosome recruitment) 
(Humphreys et al., 2005; Wang, Yanez and Novina, 2008) and post-initiation 
steps(Maroney et al., 2006; Petersen et al., 2006) 
Although the miRNA sequence indicates the mRNAs it can potentially inter-
act with, it is the proteins of the miRISC that implement the targets’ silencing. 
The miRISC also engenders deadenylation and subsequent decapping and 





1.2.3 MicroRNAs in nervous system 
1.2.3.1 MicroRNAs and neuronal development 
Considering the cellular and transcriptional complexity of the nervous sys-
tem, it  is not surprising that miRNAs are highly abundant in this tissue (Kosik, 
2006). Even within a single neuron, its complex functional architecture and 
compartmentalisation can be regulated by different sets of miRNAs (McNeill 
and Van Vactor, 2012).  
Soon after their discovery, and given their ability to regulate gene expression, 
it was proposed that miRNAs could regulate specific phases of development 
(regarding their embryonic or adult-specific expression patterns) and that 
they could have tissue-specific functions (based on their organ and cell-spe-
cific expression patterns). This was noticeably evident in the nervous system, 
where individual miRNAs or families of miRNAs have been found to regulate 
gene expression in particular neuronal cell types, at specific stages of devel-
opment, and even in specific compartments of the cell. For example, in 
highly polarised neurons, miRNA-dependent regulation of gene expression 
can occur both at the level of the entire cell or in specific subcellular com-
partments, such as axons or dendrites. These many studies show that miRNAs 
are significantly involved in the spatiotemporal regulation of neuronal gene 
expression which is essential for neural differentiation, circuit development 
and modification.  
 miRNAs are involved in determining the fate of the two major cell types, 
neurons and glia, that are present in the central nervous system (CNS) as well 
as in the peripheral nervous system (PNS). Neurons and glia emerge from the 




differentiation occurs mainly during embryonic development when many 
miRNAs are enriched, glial differentiation continues in the early postnatal 
nervous system. These processes of neurogenesis and gliogenesis involve 
many intermediate cell types as reviewed in (Paridaen and Huttner, 2014). 
miRNAs have also been associated with the regulation of adult neurogenesis 
as well, a process that is limited to few regions in the adult brain (e.g. the 
subgranular zone of the hippocampus) and likely plays a role in learning and 
memory (Luikart, Perederiy and Westbrook, 2012; Schouten et al., 2012). 
Monitoring of miRNA expression during neurogenesis in vivo has identified 
time-specific, spatially  restricted (ventral midline/midbrain dopaminergic 
progenitor pool) or cell type-specific  miRNAs, suggesting that different sets 
of miRNAs might be involved in neuronal versus glial differentiation (Rajman 
and Schratt, 2017). This is backed by the discovery of 116 miRNAs (out of 351) 
being differentially expressed in primary cultures enriched for neurons, astro-
cytes, oligodendrocytes and microglia (Jovicic et al., 2013).  
The key role of miRNAs in specific processes can be proven by disruption of 
the machinery responsible for their synthesis. Studies in the nervous system 
assessed the consequences depleting Dicer gene (which leads to absence 
of mature miRNAs) on neurogenesis. In Zebrafish, the complete absence of 
Dicer leads to major defects in the general morphology of both the CNS and 
PNS, as well as impairment of neuronal differentiation (Giraldez et al., 2005).   
1.2.3.2 miRNAs and Neuron Connectivity  
Neurons upon migration along the cortical plate, start growing axons and 
dendrites to establish functional connections. Axons comprise the presynap-
tic compartment and are essential for long distance information transmis-




specific miRNAs being enriched in axons in comparison with the neuronal 
cell body (Natera-Naranjo et al., 2010; Iyer, Bellon and Baudet, 2014; Sasaki 
et al., 2014).  
A comparison between miRNA in the cell bodies and neurites of rodent hip-
pocampal neurons showed graded distribution across the candidates and 
selective enrichment of miRNAs in dendrites versus somata (Kye et al., 2007). 
These discoveries suggest that miRNAs reach axons by active transportation 
and that they participate in the local regulation of axonal protein synthesis 
through controlling processes such as axonal branching and guidance 
(Jung, Yoon and Holt, 2012). It has been shown that BDNF-promoted axonal 
branching in the developing murine retina ganglia cells, relies on elevated 
levels of miR-132 which induces axonal branching by inhibiting the transla-
tion of Rho family GTPase-activating protein, p250GAP (Arhgap32) (Marler 
et al., 2014). Axonal branching has been shown to be induced by others 
miRNAs such as miR-124 in hippocampal neurons and miR-29a in cortical 
neurons (Franke et al., 2012; Li et al., 2014). 
1.2.3.3 miRNAs and Axon Guidance 
miRNAs are also involved in axon guidance, the directional growth of axons. 
There have been studies on several model organisms and it has been shown 
that correct axon guidance is regulated by guidance cues which are se-
creted by targets and depends on local protein synthesis (Campbell and 
Holt, 2001; Brittis, Lu and Flanagan, 2002). That implicates the function of miR-
NAs. For example, in primary rat cortical neurons, two axonally localized miR-
NAs (miR-338, miR-181c) debilitate axonal outgrowth by regulating the ex-
pression of transcripts involved in the axon guidance (Kos et al., 2016, 2017). 




programmes but axonal growth stimulated by specific guidance cues as 
well. Other findings suggest that miRNAs may be involved in mediating the 
spatiotemporal effects of guidance factors during axonal growth. For exam-
ple, microtubule-associated protein 1B (MAP1B) expression, which has an im-
portant function in outgrowth and branching (Bouquet et al., 2004;) can be 
locally regulated by miR-9 in mouse cortical neurons (Dajas-Bailador et al., 
2012) and by miR-181 in mouse peripheral sensory neurons (Wang et al., 
2015). Interestingly, it was shown that the levels of miR-9 and miR-181 in these 
conditions and by expansion the translation of Map1b mRNA, are regulated 
by BDNF (Dajas-Bailador et al., 2012) and NGF respectively (Wang et al., 
2015) These findings explain the spatiotemporal dependence of neurotro-
phin action in axon guidance. 
Several screenings have demonstrated that miRNAs can be specifically lo-
calized to the synaptodendritic (Kye et al., 2007; Siegel et al., 2009; 
Sambandan et al., 2017)compartment and also have an important function 
in dendritogenesis. For example, miR-132 has been shown to regulate the 
dendritic growth and branching of mouse and chick young hippocampal 
neurons in vitro and in vivo by repressing p250GAP (Magill et al., 2010; 
Remenyi et al., 2010; Marler et al., 2014) Mir-134 is required for the activity-
induced dendritic growth of rat hippocampal neurons in vitro by targeting 
the RNA-binding protein Pum2 In dendrites (Fiore et al., 2009). miR-134 when 
overexpressed, reduced cortical pyramidal neuron dendritogenesis in cul-
tured mouse brains (Christensen et al., 2010). Mir-9 has been shown to be 
essential for proper dendrite development in the mouse brain, by targeting 
the transcriptional repressor REST (Giusti et al., 2014) and in Drosophila mela-
nogaster sensory neurons (Wang et al., 2016), results that suggest that miR-




Most of the studies on the roles of miRNAs in neuronal development have 
focused on Bilateria, organisms that develop from three germ layers (ecto-
derm, mesoderm and endoderm). Nevertheless, miRNA pathways are not 
limited to these triploblastic animals and are likely to be present in the diplo-
blasts, as in the phyla of cnidaria and porifera.   
Experiments that demonstrate a neurodevelopmental function for miRNAs 
have followed two directions: in the first approach the full complement of 
miRNAs is disrupted by interfering with their biogenesis, while in the second 
approach the role of a single miRNA is investigated. The issue regarding the 
experiments that disrupt miRNA biogenesis, is the difficulty to understand to 
what extent the disruption of cellular functions affects the phenotype and to 
what extent the organism can bypass a single gene knockout or knock-
down.  
One defect of disrupting a single miRNA gene is that many miRNAs are mem-
bers of a family of related miRNAs whose functions could be redundant. An-
other challenge in phenotypic discovery using miRNA gene disruption tech-
niques is the unknown manner in which multiple miRNAs interact to carry out 
functions in the cell. 
 
1.2.3.4 microRNAs as regulators of local translation 
MicroRNAs have been proposed to be negative regulators of local transla-
tion in the nervous system precisely controlling physiological and morpholog-
ical changes in neurons (Schratt et al., 2006; Murashov et al., 2007; Aschrafi 
et al., 2008; Maes et al., 2009; Siegel et al., 2009; Weinberg and Wood, 2009; 
Liu and Xu, 2011; Zhou et al., 2011; Davies et al., 2018). Inhibition or activation 




subsets of mRNAs in axons. The highly conserved miR-9 has been found to 
control axonal extension and branching by regulating the levels of microtu-
bule-associated protein 1b (Map1b), an important protein for microtubule 
stability. miR-9 represses Map1b translation and is a functional target for the 
BDNF-dependent control of axon extension and branching (Dajas-Bailador 
et al., 2012). MiR-388 for example modulates axonal synthesis of the mRNAs 
that encode the mitochondrial proteins COXIV and ATP5G1  (Aschrafi et al., 
2008, 2012). This process can control the total axonal proteome and respond 
to urgent needs in restricted regions. An example of this is the regulation from 
miR-182 of Slit2-mediated axon guidance by the modulation of local trans-
lation of the respective mRNA (Bellon et al., 2017). MiRNA-132 has been 
found to be enriched in developing axons where it locally regulates Rasa1 
mRNA promoting axon extension (Hancock et al., 2014). A recent study has 
revealed that axonal transcripts have significantly longer 3’UTRs (Andreassi 
et al., 2017) so for miRNAs, which are able to repress translation by binding 
to 3’UTRs,  longer 3’UTRs allow for more rigid and even more axon-specific 
regulation by miRNAs. 
 
1.3 Neuronal degeneration and death 
1.3.1 Basic Mechanisms of neuronal cell death 
Karl Vogt was the first to note the requirement for physiological cell death in 
1842 while studying metamorphosis of amphibians (Vogt, 1842). Neuronal 
cell death was initially noticed as a loss of neurons during development. The 
first reports from 1890 and 1892 by Beard described a loss during develop-




batis (Chondrichthyes) and Lepisosteus osseus (Osteichthyes) (Beard, 1890, 
1892). 
Cell death is an extensively regulated and crucial homeostatic mechanism 
necessary to maintain tissues, organ size and normal function. Neuronal cells 
are a special type of cells that are excluded from the everyday flux of cellu-
lar birth and death. Post-mitotic neurons, following their developmental pe-
riod are required to live long in order to maintain proper circuits. During the 
developmental period though, cell death affects both mitotic neuronal pre-
cursor and postmitotic differentiated neuronal populations (Sadoul, 1998; 
Kuan et al., 2000; Buss et al., 2006). Developmental programmed cell death 
holds an important role in the establishment of functional circuits within the 
nervous system through several mechanisms such as the elimination of neu-
rons migrating to ectopic positions or innervating wrong targets, and com-
petition of neurons for limiting supplies of pro-survival factors produced by 
targets to reach optimal target innervation (Buss et al., 2006). 
There are several mechanisms that execute neuronal cell death. Firstly, there 
is apoptosis which can be triggered by two principal pathways: the intrinsic 
(mitochondrial) pathway and the extrinsic (death receptor) pathway. The 
extrinsic apoptosis pathway is triggered by the ligation of tumour necrosis 
factor (TNF)-family death receptors on the cell surface. Receptor ligation can 
lead to the recruitment of Fas-associated death domain protein (FADD), 
which subsequently binds pro-caspase-8 molecules, which leads to autopro-
teolysis and activation of caspase-8.  
Upon its activation, caspase-8 may activate downstream effector caspases 
directly through proteolytic cleavage or indirectly by cleavage of the BH3-
only protein Bid to produce tBid which translocates to mitochondria to in-
duce Bax activation and mitochondrial outer membrane permeabilization 




The intrinsic apoptosis pathway centres on the regulation of MOMP by the 
Bcl-2 family proteins (Sadoul, 1998; Cheng et al., 2001). Proteins of the Bcl-2 
family share homology within at least one of up to four Bcl-2 homology (BH) 
domains that are necessary for the homo- and heterotypic interactions that 
determine the decision to undergo MOMP. The pro-apoptotic Bax and Bak 
contain BH1–3 and are essential for the execution of apoptosis via the intrin-
sic pathway (Cheng et al., 2001; Wei et al., 2001; Zong et al., 2001), though 
it has come to light a new but yet unknown Bax/Bak-independent intrinsic 
apoptotic pathway (Zamorano et al., 2012).  In neurons Bak is expressed as 
an alternately transcribed product (N-Bak) that is translationally repressed 
and does not participate in apoptosis (Jakobson et al., 2013b). Therefore, 
the induction of intrinsic apoptosis in neurons is completely dependent on 
Bax expression and activation. Deletion and inhibition of Bax has been 
shown to prevent aberrant neuronal cell death in several in vitro and in vivo 
models of neurodegeneration (Deckwerth et al., 1996; Miller et al., 1997; 
Xiang et al., 1998; Johnson et al., 1998; Gibson et al., 2001; Wong et al., 2005; 
Gould et al., 2006; Smith and Deshmukh, 2007; Tehranian et al., 2008; 
Jakobson et al., 2013a; D’Orsi et al., 2015, 2016). 
Autophagic cell death, paraptosis and phagoapoptosis are different mech-
anisms of neuronal cell death (Fricker et al., 2018),the analysis of which does 
not serve a particular goal concerning this thesis.  
1.3.2 Neuronal Death induced by stimuli 
Apart from mechanisms leading to it, neuronal cell death can also be in-
duced by various important stimuli. To begin with, neuronal cell death can 
be induced by the lack of neurotrophic factors (NTFs). According to the neu-




depends on competition for limiting amounts of NTFs synthesised by their tar-
get fields or lack of these factors if the axons go off course (Purves, 1986). 
Catalytic role to the proposal and validation of this hypothesis played the 
discovery of NGF by Rita Levi-Montalcini in the 50s  (Levi-Montalcini, 1964; 
Aloe, 2004)and later of the brain derived-neurotrophic factor (BDNF), NT3 
and NT4/5 (Davies, 1988)and their specific Trk tyrosine kinase receptors 
(Korsching, 1993). Later important discoveries were that of glial-derived neu-
rotrophic factor (GDNF) family along with their specific receptor subunits and 
signaling receptor Ret tyrosine kinase  (Airaksinen, Titievsky and Saarma, 
1999; Baloh et al., 2000), the LIF/CNTF(ciliary neurotrophic factor) cytokine 
family that is substantial after injury and their composite receptors 
(Richardson, 1994; Baloh et al., 2000) and insulin-like growth factor I(IGF-1) 
(Nikolić, Gardner and Tucker, 2013). 
A neuron’s death can lead to death of neurons connected to it. This process 
is called transneuronal degeneration or secondary neuronal loss and the de-
generation can occur either anterograde or retrograde. Transneuronal de-
generation results from loss of synaptic inputs to neurons while retrograde 
transneuronal degeneration results from the loss of synaptic outputs (Fricker 
et al., 2018).  
Cell death can also be induced by aberrant mitosis, also called “mitotic ca-
tastrophe” (Castedo et al., 2004; Vakifahmetoglu, Olsson and Zhivotovsky, 
2008; Vitale et al., 2011)a process that has been suggested to contribute to 
neuronal death in neurodegenerative diseases (Yurov, Vorsanova and 
Iourov, 2011; Seward et al., 2013; Tokarz, Kaarniranta and Blasiak, 2016).  
Excitotoxicity, cell death due to high levels of excitatory neurotransmission 
(Olney, 1971) and “oxidative glutamate toxicity” or “oxytosis”, glutamate-in-




and consequent oxidative stress (Schubert and Piasecki, 2001) have been 
reported. 
The accumulation of aggregated/misfolded proteins is a major cause of neu-
ronal dysfunction and death in neurodegenerative disorders including Alz-
heimer’s disease (tau and amyloid β), Parkinson’s disease (α-synuclein), Hun-
tington’s disease (huntingtin), prion diseases (prion protein), and ALS (super-
oxide  dismutase 1, TDP-43, FUS) (Fricker et al., 2018). 
Other causes of neuronal cell death are ROS and RNS, reactive molecules 
derived from oxygen and reactive molecules derived from NO respectively. 
ROS and RNS have been implicated in neuronal death in various ways and 
in almost all types of neuropathology and neurodegenerative diseases 
(Cobb and Cole, 2015). 
 
Microglia, the macrophages of the brain, are able to orchestrate the immu-
nological response by interacting with infiltrating immune cells. They are es-
sential in neuronal survival as they produce neurotrophic factors and phag-
ocytose dead cells, cellular debris, protein aggregates and pathogens. In 
the healthy brain, microglia are in a state of “rest”, immobile with long, motile 
processes but if they detect inflammatory stimuli, they become activated, 
motile and express iNOS and cytokines (Wolf, Boddeke and Kettenmann, 
2017). Activated microglia can kill neurons with release of TNF-α, glutamate, 
cathepsin B and/or reactive oxygen and nitrogen species (RONS) which can 
induce apoptotic, excitotoxic and necrotic death of the surrounding neurons 
(Block, Zecca and Hong, 2007; Brown and Vilalta, 2015; Kim, Kim and Yenari, 
2015). 
Lastly, axon death and cell death can be induced by axotomy which leads 
to different death mechanisms in different neuronal compartments. A widely 
studied and well understood mechanism is Wallerian degeneration which is 




1.3.1 Wallerian Degeneration, a deathly pathway 
As previously described, neurons acquire at least two self-destruction pro-
grammes. They have an intracellular death programme for apoptosis when 
they are injured, infected or no longer needed. Moreover, they seem to 
have a molecularly distinct self-destruct programme in their axon. These in-
dependent and different death pathways that somata and axons develop 
can be activated, more than one of which, in the same cell (Raff, Whitmore 
and Finn, 2002). In 1850, Augustus Waller first described the degeneration se-
quence of separated nerve fibres from their cell bodies. This pathological 
process in which axon degeneration is triggered by axonal injury at a specific 
site and time and simultaneously affects all axons is called Wallerian degen-
eration (Waller, 1851). This process begins with rapid axonal disintegration of 
axoplasm and axolemma, breakdown of myelin sheath and activation of 
microglia followed by clearance of the tissue debris by Schwann cells and 
invading macrophages (Buss et al., 2004). In the peripheral nervous system, 
Wallerian degeneration is characterised by three distinct phases. Firstly, 
minutes after the transection, proximal and distal to the injury site short ax-
onal stumps are affected by acute degeneration. This process is defined as 
acute axonal degeneration (AAD) (Kerschensteiner et al., 2005). This is fol-
lowed by a latent phase where no morphological changes take place and 
the axons remain electrically excitable. This lag between injury and degen-
eration varies amongst different species from 20 to 48 hours in young rats 
(Miledi and Slater, 1970)  and mice (Beirowski et al., 2005) to several days in 
primates including humans (Gilliatt and Hjorth, 1972; Chaudhry and 
Cornblath, 1992). The latent phase precedes a rapid disintegration phase 




fragmentation and the presence of ovoids of degenerating myelin (Conforti, 
Gilley and Coleman, 2014). 
Interestingly, the Wallerian mechanisms is not limited to injury. Uninjured, wild-
type axons degenerate in a Wallerian like manner after NGF withdrawal, ex-
posure to vincristine, blockage of axonal transport, inflammation, ischemia 
and several other stresses. A common denominator of many of these stresses 
in the impaired delivery of nicotinamide mononucleotide adenylyl transfer-
ase 2 (NMNAT2) to distal axons (Conforti, Gilley and Coleman, 2014).  
1.3.2 The WLDS mouse 
After decades of study, Wallerian Degeneration was thought to be a passive 
degenerative process, the inevitable consequence of axons separating and 
losing support from their cell bodies. In mammals within hours to days of ax-
onal injuries, explosive degeneration of the axonal cytoskeleton in the distal 
nerve stump takes place. Examples of prolonged survival of truncated axons 
had been found only in invertebrates and poikilotherms (Bittner, 1991). This 
belief came to change after the serendipitous discovery of a spontaneous 
dominant mutation in mice whose transected axons remain intact ten times 
longer than normal (Lunn et al., 1989). The mouse was later named Wallerian 
Degeneration Slow (WLDS).  PNS or CNS axons of the Wlds mouse survive for 
up to 4 weeks and support action potential and the bidirectional redistribu-
tion of proteins for at least 2 weeks (Lunn et al., 1989; Glass and Griffin, 1994). 
Wlds  derived SCG and DRG primary neuronal cultures show protection for 
more than 72 hours when wild-type axons survive for 6-16 hours Synaptic ter-
minals are preserved in the Wlds mice but after axotomy,(Beirowski et al., 
2005; Conforti et al., 2009) synapse withdrawal is faster than the degenera-
tion of the axon shaft especially in older animals (Adalbert et al., 2005; 




apart from a nerve degeneration defect and reduced plasticity following 
injury that is secondary to the delayed degeneration (Bisby and Chen, 1990; 
Collyer et al., 2014). Evidence show that the Wlds abnormality is intrinsic to 
neuronal axons rather than monocyte or glia cells (Crawford et al., 1995). 
The precise contribution of glial cells in Wallerian Degeneration is still under 
investigation. 
1.3.3 The WLDS gene and protein 
Studies showed that the slow Wallerian Degeneration phenotype is caused 
by the over-expression of the WLDS fusion protein. The Wlds chimeric gene is 
mapped to mouse chromosome 4 where a tandem triplication of an 85-kb 
genomic region has been identified. The resulting WLDS protein contains the 
full length nicotinamide mononucleotide adenylyl transferase 1 (NMNAT1) at 
the C-terminal end, fused with 70 N-terminal amino acids of the N-terminus 
portion of ubiquitin ligase E4B (Conforti et al., 2000). The two domains of the 
WLDS protein are linked by an 18 amino acid sequence (the epitope of the 
specific Eld18 antibody) which was originally part of NMNAT1 5’ untranslated 
region (UTR) (Samsam et al., 2003; Coleman and Freeman, 2010). It has been 
shown that the protective phenotype is dose-dependent in axons as well as 
in synaptic terminals (Adalbert et al., 2005). It is interesting that the protective 
effects of NMNAT/WLDS  are maintained even in axons empty of mitochon-
dria (Kitay et al., 2013). Transgenic expression of the WLDS gives protection to 
mice, rats, zebrafish, Drosophila and primary human neuronal cultures (Lunn 
et al., 1989; MacDonald et al., 2006; Martin et al., 2010; Kitay et al., 2013). The 
presence of NMNAT1 gives WLDS intrinsic ΝΜΝΑΤ enzymatic activity (Mack 
et al., 2001). On the other hand, the fusion protein contains only 6% of the 




Consequently, WLDS is unlikely to have ubiquitin ligase activity (Coleman and 
Freeman, 2010; Conforti, Gilley and Coleman, 2014). 
 
1.4 NAD metabolism and axon degeneration 
1.4.1 NMNATs and NAD+ metabolism 
The importance of NAD+ metabolism for axonal survival emerged from the 
discovery of WLDS which contains NMNAT1, an enzyme that catalyses NAD+ 
synthesis from ATP and NMN (Magni et al., 2004a). Apart from its action as a 
co-enzyme in redox reactions NAD+ and its metabolites have key signalling 
roles. ADP ribose (ADPR), cyclic ADPR and nicotinic acid adenine dinucleo-
tide phosphate (NAADP) act as key second messengers in Ca2+ signalling 
(Koch-Nolte et al., 2009). ADP also contributes to post-translational protein 
modifications such as mono or poly-ADP ribosylation, which is catalysed by 
mono (ADP ribose) transferases (ARTs) and poly (ADP ribose) polymerases 
(PARPs), and deacetylation which is catalysed by sirtuins. 
NMNAT enzymes can be found in all organisms. They catalyse the final step 
of NAD biosynthesis in de novo and salvage pathways. There are three sal-
vage pathways each of which uses a different substrate: Nicotinic Acid (ΝΑ), 
nicotinamide (NAM) and nicotinamide riboside (NR) which are all members 
of the vitamin B3 family and are found in plenty of foods such as eggs, fish, 
meat, dairy, vegetables, wheat and corn (Bieganowski and Brenner, 2004; 
Bogan and Brenner, 2008; de Figueiredo et al., 2011).  
 In the NA pathway, also known as Preiss and Handler pathway (Preiss and 




to produce nicotinic acid adenine dinucleotide (NaAD). In the next step 
NAD synthetase converts NaAD to NAD+. In the second salvage pathway, 
ΝΑΜ is converted to nicotinamide mononucleotide (NMN) by nicotinamide 
phosphoribosyl transferase (NAMPT). Following that, NMN is converted to 
NAD+ by NMNATs. In the de novo pathway or kynurenine pathway, the es-
sential aromatic amino acid tryptophan is converted to NaMN and then to 
NAD+ through the Preiss-Handler pathway (Magni et al., 2004a; Di Stefano 
and Conforti, 2013). Tryptophan though, is inadequate to fulfil NAD+ needs 
on its own and emphasizes the importance of the salvage pathways (de 
Figueiredo et al., 2011).  
Interestingly, Di Stefano et al. found that blocking NAMPT proved to be axon-
protective despite lowering NAD+ levels. They showed that after axon injury, 
NMN accumulates and promotes degeneration. They also found that NMN 
promotes Wallerian-like degeneration without physical injury. (Di Stefano et 
al., 2015) 
Concerning mammals, NAD+ is hydrolysed by several enzymes such as 
mono-ADP-ribosyl transferases (MARTs), poly-ADP-ribose polymerases 
(PARPs), sirtuins (SIRTs), and ADP-ribosyl cyclases producing NAM (Rongvaux 
et al., 2003; Hassa et al., 2006; Bogan and Brenner, 2008; Di Stefano and 
Conforti, 2013; Mori et al., 2014; Imai, 2016).  
NAD+ takes part in a plethora of intracellular processes. It is a cofactor in 
redox reactions and plays an important role in glycolytic and mitochondrial 
ATP synthesis. It also has a function in the regulation of post-translational pro-
tein modifications and Ca2+ signalling (Belenky, Bogan and Brenner, 2007; 
Chiarugi et al., 2012; Di Stefano and Conforti, 2013). Moreover, it has been 
shown that the decline in systemic NAD+ biosynthesis can be a trigger for 




NAD+ biosynthesis deteriorates with age in multiple organs and tissues, such 
as pancreas, adipose tissue, skeletal muscle, liver, and brain through reduc-
tion of the activities of SIRT1 and other sirtuins in those organs and tissues 
(Imai, 2016).  
1.4.2 NMNAT 
1.4.2.1 The ΝΜΝΑΤ2 protein 
The necessity of the enzymatically active NMNAT1 for WLDS neuroprotective 
function shed light to the link between NMNATs/NAD biosynthetic pathway 
and axon degeneration. Mammals have three NMNAT isoforms all of which 
have the same enzymatic activity but are distributed in different cellular 
compartments. NMNAT1, which is present in WLDS, is located in the nucleus 
(Magni et al., 2004b). NMNAT2 can be located in the cytoplasm and the 
axons associated with Golgi-derived vesicles while NMNAT3 is found in mito-
chondria (Berger et al., 2005). In Drosophila there has been only one NMNAT 
gene which produces dNMNAT that is widely distributed in the cell (Zhai et 
al., 2006). 
Amongst the three isoforms, only the depletion of NMNAT2 by a siRNA in-
duces degeneration in uninjured SCG axons in vitro. WLDS protects the neu-
ron in this experimental condition, while endogenous NMNAT1 and NMNAT3 
fail to do so. Inhibiting the protein synthesis leads to quick depletion of 
NMNAT2, which suggests a fast turnover rate and consequent axonal de-
generation (Gilley and Coleman, 2010). Under physiological conditions 
NMNAT2 is mainly synthesized in the soma and reaches the axons through 
fast axonal transport in association with Golgi-derived vesicles (Milde, Gilley 




communication with Dr. Sotelo-Silveira) and in human tibial nerve (Ray et al., 
2018) Injury disrupts the delivery of soma-synthesised NMNAT2 which explains 
the observed depletion. WLDS  is significantly more stable than NMNAT2 and 
is hence not quickly depleted in transected axons (Gilley and Coleman, 
2010). Yet, inhibition of protein synthesis in the somata using compartmental-
ised cultures leads to distal axon degeneration.  
ΝΜΝΑΤ2 is a remarkably labile protein with a particularly short half-life (<1 
hour) and its turnover is mediated by the ubiquitin-proteasome system 
(Milde, Gilley and Coleman, 2013). NMNAT2 overexpression has been found 
to be protective in SCG neurons in vitro (Gilley and Coleman, 2010). 
1.4.2.2 Nmnat2 is a survival factor for the axon 
Axotomy has been found to lead to depletion of several axonal proteins but 
NMNAT2 appears to be critical and sufficient to induce degeneration. 
NMNAT2’s role in axonal health seems to extend beyond regulation of Wal-
lerian Degeneration. Indeed, studies reveal an essential role of NMNAT2 in 
axon growth and maintenance (Hicks et al., 2012; Gilley et al., 2013). Knock-
ing out NMNAT2 leads to serious defects in perinatal lethality and peripheral 
innervation in mice. Primary SCG and DRG neuronal cultures of NMNAT2 null 
mice are not able to develop full length axons which reflects deficiency of 
axon elongation and not dying-back degeneration, axons gradually degen-
erating from the synaptic towards the cell body (Gilley et al., 2013). NMNAT2, 
as mentioned before, is transported through attachment on Golgi-derived 
vesicles. Notably, disruption of its palmitoylation-dependent attachment to 
vesicles results in expanded NMNAT2 cytoplasmic distribution and conse-




show increased stability, can reach the axons and protect them (Milde et al., 
2013; Milde, Gilley and Coleman, 2013; Milde and Coleman, 2014). 
There is though controversy regarding the mechanism of NMNAT-mediated 
neuroprotection. The prevailing hypothesis is that NMNAT overexpression pro-
vides continuous enzyme activity in injured neurons and thus prevents the 
consequent decrease in NAD+ and the accumulation of the precursor NMN 
(Gerdts et al., 2016). Recent studies though, revealed that NAD+ depletion 
following axon injury is due to massive depletion of NAD+ by SARM1 (sterile 
alpha and TIR motif-containing 1). The overexpression of cytoplasmic 
Nmnat1, rather than altering NAD+ synthesis, blocks SARM1-dependent 
NAD+ , (Sasaki et al., 2016). So, NMNAT-mediated axon protection relies on its 
ability to block SARM1 signaling, but this does not rely on enzymatic conver-
sion of NMN to NAD+. 
Interestingly, Di Stefano et al. showed that NMN accumulates after nerve in-
jury promoting axon degeneration. Despite lowering NAD+, inhibitors of 
NAMPT are neuroprotective in injured axons and synapses but exogenous 
NMN abolishes this protection. This suggests that NMN accumulation in axons 
after NMNAT2 degradation might promote degeneration. In conclusion, they 
proposed that the mechanism by which NMNAT2 and WldS protein confer 
axon survival is by the limitation of NMN accumulation (Di Stefano et al., 
2015). 
Οn a more recent work, it was shown that NMN deamidase, a bacterial en-
zyme, can also delay axon degeneration in zebrafish larvae and transgenic 
mice.  Similarly to overexpressed NMNATs, NMN deamidase decreases NMN 
accumulation in injured mouse sciatic nerves and preserves some axons up 
to three weeks, even when it is expressed at a low level. Moreover, NMN de-
amidase rescues axon outgrowth and perinatal lethality in a dose-depend-
ent way in NMNAT2-depleted mice. These findings further support a pro-de-




2017). Loreto et al showed that in vitro and in vivo axotomy leads to an in-
crease of intra-axonal Ca2+ which can be suppressed by genetic or pharma-
cological reduction of NMN levels. NMN requires SARM1 to induce Ca2+ influx 
and axon degeneration. Although inhibition of NMN synthesis and SARM1 de-
letion block rise of Ca2+ and preserve axonal integrity, they do not prevent 
early mitochondrial dynamic changes. Their work indicates that NMN and 
SARM1 act in a common pathway climaxing in intra-axonal Ca2+  increase 
and fragmentation and that mitochondrial dysfunctions are not causative in 
NMN-induced degeneration (Loreto et al., 2015). 
An alternative is that NMNAT provides neuroprotection via an enzyme-inde-
pendent function, which leads to the hypothesis that NMNAT mediated pro-
tection is chaperone-dependent (Zhai et al., 2008; Brazill et al., 2017).  
1.4.2.3 NMNAT2 and the brain 
NMNAT2 is highly expressed in the mammalian brain, and NMNAT2 mRNA 
levels have been found reduced in Parkinson’s Disease (PD), Huntington’s 
Disease (HD), Alzheimer Disease (AD) and tauopathy patients (Ali et al., 
2016). The NMNAT2 mRNA levels show a positive correlation with cognitive 
function and a negative one with pathological features of AD (Ali et al., 
2016). In AD brains NMNAT2 mRNA and protein levels are reduced and 
NMNAT2 co-localises with aggregated tau proteins (Ali et al., 2016). Overex-
pressing NMNAT2 leads to the reduction of the pathological accumulation 
of hyperphosphorylated tau without altering total tau levels (Ljungberg et 
al., 2012; Ali et al., 2016). NMNAT2 has been shown to prevent protein dena-
turation and to promote protein refolding with similar activity to Hsp70. Inter-
estingly, the enzymatically-dead NMNAT2 mutants which lack NAD synthetic 




of NMNAT2 increases the susceptibility of cortical neurons to proteotoxic 
stress (Ali et al., 2016). 
Single nucleotide polymorphisms within the NMNAT2 gene genomically as-
sociate it with human cognition (Davies et al., 2018). A positive correlation 
between NMNAT2 mRNA levels and cognition has also been identified (Ali 
et al., 2016). Reduced mRNA levels have also been observed in Parkinson’s, 
Alzheimer’s and Huntington’s disease patients (Ali et al., 2013, 2016) and 
Nmnat2 mRNA levels are down-regulated prior to neurodegeneration in a 
mouse model of human tauopathy (Ljungberg et al., 2012). These findings 
suggest that a low or decreasing expression of NMNAT2, a key regulator of 
axon health, may be conducive to clinical and subclinical phenotypes.  
Crucially, NMNAT2 mRNA levels appear to vary widely between individuals 
in the human population (Ali et al., 2016), so a better understanding of how 
reduced (but not absent) NMNAT2 expression influences axon survival, either 
constitutively or in response to neurodegenerative stresses, is needed. 
Interestingly, the neuroprotective action of NMNATs expands beyond their 
NAD synthase enzymatic activity they act as molecular chaperones (Ali et 
al., 2013). Early studies demonstrating the chaperone function of NMNATs 
noticed that loss of Drosophila NMNAT (dNMNAT) caused severe and rapid 
neurodegeneration, which could be rescued by enzymatically inactive 
dNMNAT (Zhai et al., 2006). Moreover, dNMNAT overexpression in Drosoph-
ila  turned out to be protective against spinocerebellar ataxia 1 (SCA1)-in-
duced neurodegeneration, a disorder characterised by the aggregation of 
misfolded proteins (Zhai et al., 2008). These findings unveiled the molecular 
chaperone function of dNMNAT independent of the NAD synthase function 




In vertebrates, a recent study described a molecular chaperone role for 
NMNAT2 in regulating protein homeostasis in neurodegeneration-related 
scenarios. The study showed that overexpression of NMNAT2 in the brain re-
duced pathological signs of neurodegeneration in rTg4510 mice, a trans-
genic model of frontotemporal dementia with parkinsonism linked to chro-
mosome 17 (FTDP-17), which expresses the human protein Tau with the mis-
sense mutation P301L (Ljungberg et al., 2012). These results support the theory 
that NMNAT2 might be acting as a molecular chaperone protecting against 











1.5 Aim of the Thesis 
 
As previously stated, only NMNAT2 out of the three NMNAT isoforms in mam-
mals, seems to have the biggest influence over axon survival under physio-
logical conditions as solely depletion of this isoform causes a primary axonal 
phenotype either in vitro or in vivo.  
Although, NMNAT2 protein has been studied extensively in the peripheral 
nervous system, we still need to elucidate its role and function in central nerv-
ous system. 
In this work we decided to study NMNAT2 protein’s effect on cortical neurons 
as well as its putative regulation by microRNAs. In order to do so, we set three 
objectives: 
Firstly, the investigation of the role of NMNAT2 overexpression in mouse pri-
mary cortical neurons in axonal growth and degeneration. 
Secondly, the identification of miRNAs with the potential to target NMNAT2 
using bioinformatic methods and relevant existing literature. 
Lastly, the investigation of the effect of overexpression of these microRNAs 








Chapter 2: Materials and Methods 
2.1 Cell cultures 
2.1.1.  Animals and primary cortical cultures  
All animal studies conformed to the institution’s ethical requirements in ac-
cordance with the 1986 Animals (Scientific Procedures) Act. 
C57/BL6 mouse embryos in E16.5 developmental stage were culled and their 
brains were removed. The brain cortices were dissected and the meninges 
separated under a stereoscopic microscope. The acquired tissue was incu-
bated in Hanks Balanced Salt Solution (HBSS, Ca2+ and Mg2+ free; Gibco) with 
1mg/ml trypsin and 5mg/ml DNAseI (both Sigma) at 37°C/5% CO2 for 30 min. 
After treatment with 0.05% (v/v) trypsin inhibitor (Life Technologies), the tissue 
was washed in Neurobasal media (Gibco) and 5mg/ml DNAseI was added 
before mechanical dissociation of the tissue. The cells were finally washed in 
Neurobasal media and spun down at 250x g for 5 min. Dissociated cells were 
then resuspended and plated in Neurobasal media supplemented with 1x 
GlutaMax and 2% (v/v) B-27 (Gibco), according to experimental require-
ments. The procedure was conducted in a class II cabinet apart from the 
dissection, which was performed under the stereoscopic microscope. 
2.1.1.1 Dissociated cortical cultures 
The dissociated cortical cells were resuspended in supplemented Neuro-
basal media to a final density of 10 x 106 cells/ml. The cortical cell suspension 
was diluted down and plated in 6-well plates (Corning) containing 22x22mm 




cells/cm2 and incubated at 37°C, 5% CO2. Prior to plating, glass coverslips 
were coated with 50μg/ml poly-L-ornithine (PLO; Sigma-Aldrich) overnight 
and washed twice with sterile distilled water. Neurons were allowed to grow 
for 24 hours before being transfected.  
2.1.1.2 Functional assays of axonal growth 
For these experiments, cortical primary cultures in 6-well configuration 
(1.75x105 cells/cm2) were transfected 24h after plating using: 5μL/well of 
Lipofectamine 2000 (LF 2000; Life Technologies) and 250μl/well of Opti-MEM 
reduced serum media (Life Technologies), in accordance with the manu-
facturer’s instructions. In short, LF 2000 was incubated with 125μl/well of Opti-
MEM for 15 min and, in parallel, pmaxGFP plasmid (Lonza) and miRNA mimics 
or plasmid constructs were incubated with 125μl/well of Opti-MEM. The re-
action mixes were then mixed together and incubated for 30 minutes at RT 
to allow nucleic acid-loaded liposome formation before they were finally 
loaded to the cell wells. In all functional assays of axonal growth cells were 
transfected for 72 hours prior to analysis. 
2.1.1.2.1 Transfection with miRNAs  
To test the effect of overexpression of mmu-miR-494-3p, mmu-miR-132-3p, 
mmu-miR-129-1-3p and mmu-miR-181a-5p on axonal length, primary cortical 
cultures were transfected with miRCURY LNA microRNA mimics of the afore-
mentioned microRNAs and microRNA mimic Control (Qiagen). These are 
short oligonucleotides with a Locked Nucleic Acid (LNA). Briefly, LNAs are 
modified RNA nucleotides in which the 2′-O and 4′-C atoms of the ribose are 
joined through a methylene bridge. This additional bridge limits their flexibil-




known as ‘inaccessible RNA’ (Koshkin et al., 1998). Cells were co-transfected 
with 1 μg of pmaxGFP (Lonza and each microRNA mimic at a final concen-
tration of 20 nM.  MicroRNAs were all tested at the concentration of 20 nM. 
2.1.1.2.2 Transfection with NMNATs 
To test the effect of overexpression of NMNAT2, enzymatically-dead NMNAT2 
and NMNAT1 on axonal length, primary cortical cultures were co-trans-
fected with 1 μg pmaxGFP and 1 μg of empty pCMV-TAG-2B vector or 
pCMV-TAG-2B-NMNAT2, pCMV-TAG-2B-NMANT2 (enzymatically-dead) and 
pCMV-TAG-2B-NMNAT1 respectively. The plasmids were a gift from Professor 
Coleman, University of Cambridge. 
2.1.2. Mammalian cell lines  
 
Neuro2a cells were maintained and grown in Dulbecco’s modified Eagle’s 
medium (DMEM; Sigma) supplemented with 10% (v/v) fetal bovine serum 
and 1% (v/v) Penicillin-Streptomycin (both Sigma) in a humidified incubator 
at 37°C, 5% CO2. Before each experiment, cells were detached with 1x tryp-
sin-EDTA (Sigma) and washed with supplemented DMEM.  
 
2.1.2.1 Transfection of Neuro2A cells with microRNAs 
Neuro2A cells have significantly higher transfection efficiency compared to 
primary cortical neurons and this makes them an ideal model to test the ef-




extremely challenging.  Neuro2A cell cultures were seeded at a density of 
1x105 cells per well in 12-well plates (Greiner) and transfected after 24h with 
miR-129, miR-181 mimics and mimic negative control (to final concentration 
of 50 nM), 1.5 μL of Lipofectamine 2000 and 200 μL of Opti-MEM, following 
the procedure described above for transfection of cortical neurons. All ex-
periments were conducted in duplicates.  
Total RNA was extracted 48h and 72h for quantification of NMNAT2 and 
GAPDH mRNA levels by RT-qPCR as described on the next chapter. 
2.2 Microscopy and Image analysis 
Cortical neurons cultured on coverslips were fixed in 4% (w/v) paraformalde-
hyde (3.6% sucrose (w/v), 1x PBS, 5mM MgCl2, pH 7.4; ThermoFisher) for 25min 
at Room Temperature, washed with 1x PBS three times and mounted with 
Vectashiled Hardset mounting media with Dapi (vector Labs). In each inde-
pendent experiment, axons of approximately 50 GFP-positive neurons were 
measured per condition. The axon was defined as the neurite being at least 
3 times the length of any other neurite projecting from the cell(Dajas-Baila-
dor et al., 2012) and was measured using Fiji software (Schindelin et al., 2012). 
Intact axons of healthy neurons were traced from the soma to the tip of the 
longest projection αs shown in Figure 6. Axon length measured on DIV5 as 
later on, it becomes extremely difficult to measure axonal length of individ-
ual neurons as axons from several neurons cross each other giving a rather 
unclear image under the microscope. Data were collected from 3 to 6 indi-
vidual experiments, normalised to the average of the control and expressed 
as percentage of control, mean±s.e.m. 
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2.3 Molecular Analysis 
2.3.1 RNA extraction 
Total RNA was isolated from Neuro2A cultures at 48 and 72h after transfec-
tion by the phenol-chloroform extraction method using TRIzol Reagent (Invi-
trogen) for extraction of total RNA, according to manufacturer’s instructions. 
In brief, culture media were removed and the cells were washed with PBS 
(ThermoFisher), the cells were then treated with 250μl of TRIzol (per well), 
were homogenized, scrapped off and put into LoBind tubes (Eppendorf) 
were a mix ed with 1/5 volume of chloroform (ThermoFisher) followed. 
Afterwards, centrifugation was performed at 12000xg/4°C for 15 min, the 
aqueous phase was mixed with equal volume of isopropanol (ThermoFisher) 
and incubated at -20°C overnight. Total RNA was precipitated at 12000x g/ 
4°C for 30 min and the pellet further washed twice in 75% (v/v) ethanol at 
12000xg/4°C, for 30 min (ThermoFisher). RNA pellet was left to dry until it ap-
peared like a clear jell and then was resuspended in Hyclone nuclease-free 
water (GE Healthcare). All steps were conducted in an RNAse-free 




environment, using nuclease-free tubes and reagents, filtered pipette tips 
and, where adequate, on ice to further control the RNAse-dependant deg-
radation of the samples. 
2.3.2 Quantification of NMNAT2 mRNA levels by real time qPCR  
Reverse transcription for cDNA synthesis was performed using 100 ng of total 
RNA extracted from N2A cells using SuperScript IV reverse transcriptase and 
Oligo(dT)20 primers (both Invitrogen), in accordance with the manufacturer’s 
instructions. PCR amplification was performed using PowerUp SYBR Green 
(Applied Biosystems) following manufacturer’s instructions, using 1.5μL of 
template cDNA or nuclease free water (non-template control) per amplifi-
cation reaction.  
 
 
 PCR amplification 






Extension 72°C, 2min 
 
RT reaction 20 μL 
Oligo d(T)20 primer 1 μL 
10 mM dNTP mix 1 μL 
RNA (20 ng/μL) 5 μL 




5x Buffer 4 μL 
DTT (100 mM) 1 μL 
RNaseOUT Rnase 
Inhibitor 1 μL 











As for miRNA RT-qPCR, amplification reactions were set up in duplicate in a 
96-well configuration and run on a StepOne Plus Real-Time PCR instrument, 
with melting curve analysis being conducted in standard instrument condi-
tions, showing single melt curves for all primer pairs. Primer sequences target-
ing Nmnat2 transcript were selected from (Cheng et al., 2013) with the fol-
lowing sequences Forward: 5’-GTGATTGGCG GGATTGTCTCT-3’ and Re-
verse: 5’-TCTTCATCAGGTC TCGAT GGT-3’ (IDT). As a reference gene we 
used GADPH with the following primers Fοrward: 5’-CTGCACCAC-
CAACTGCTTAG-3’ and Reverse: 5’-ACAG CTTCTGGGTGGCAGT-3’. 
2.3.3 Real-Time qPCR analysis  
 
The threshold was set at the same level for all targets and Ct (Cycle Thresh-
old) values were acquired using StepOne Software v2.3 (Applied Biosys-
tems). Data was analysed using the comparative 2-ΔΔCt method for calcula-
tion of the relative expression of each target gene based on the formula: 
 
Fold difference = 2-ΔΔCt 
where 
ΔCt sample - ΔCt calibrator = ΔΔCt 
Ct NMNAT2 s - Ct GADPH s= ΔCt sample 
Ct NMNAT2 c - Ct GADPHc=ΔCt calibrator 
For studying Nmnat2 expression in N2A cells transfected with microRNA mim-
ics, NMNAT2 levels were normalised to the levels of GAPDH which is a com-
monly used as reference gene as its ΔCt<1.5 amongst all samples within 





2.4 Statistical analysis  
 
Data are expressed as Mean ± SEM. Statistical analysis was performed using 
Shapiro-Wilk test to evaluate normality and one-way ANOVA with Dunnett’s 
post-hoc analysis or One sample t-test, where applicable, with P-values less 
than 0.05 being considered as significant for any set of data. Stars represent 
statistical significance with p= * <0.05, ** <0.01, *** <0.001, ****<0.0001. Data 
were analysed using GraphPad Prism version 7.0 and Microsoft Excel (Mi-





Chapter 3: Results 
3.1 Nmnat2 and Mouse Primary Cortical Neurons  
3.1.1 Introduction 
Several studies have shown that the NMNAT2 transcript is enriched in the 
brain in comparison to other tissues (Raffaelli et al., 2002; Yalowitz et al., 2004) 
though it has also been detected in muscle and heart (Yalowitz et al., 2004). 
NMNAT2 mRNA levels seem to vary broadly among individuals in human 
population (Ali et al., 2016), hence the need for a deeper understanding of 
how Nmnat2 levels can be controlled and how they can influence axon sur-
vival and function both constitutively and in response to neurodegenerative 
stress. Overexpression of Nmnat1, -2, or -3 in neurons has been demonstrated 
to slow the rate of axon degeneration in vivo and in vitro(Sasaki, Araki and 
Milbrandt, 2006; Conforti et al., 2009; Wen et al., 2011; Kitaoka et al., 2013; 
Sasaki et al., 2016) especially after axon injury in PNS neurons. 
NMNAT2 function has been broadly studied in the peripheral nervous system 
but a deeper understanding of its role in the central nervous system is still 
lacking. In PNS neurons, NMNAT2 overexpression has been shown to be pro-
tective against axon degeneration and by extension neurodegeneration.  
However, Mayer et all found that overexpression of exogenous Nmnat2 was 
toxic to primary cortical neurons and led to pervasive cell death. More spe-
cifically, they infected primary cortical neurons with lentivirus expressing ei-
ther Nmnat2-FLAG or Nmnat2 C164S/C165S-FLAG.  4 days after infection 
when the cultures were fixed and probed with an anti-FLAG antibody, they 
observed that Nmnat2, but not Nmnat2 C164S/C165S, was toxic to neurons. 




Characterization of Nmnat2 and they did not test other NMNATs (Mayer et 
al., 2010).  
Overall these studies demonstrate the need for further studies of the role of 
NMNAT2 in CNS neurons, as results reported might indicate the need for a 
tight regulation of NMNAT2 levels in neuronal models in general. 
3.1.2 Overexpression of NMNATs in cortical neurons 
As a first approach to test the effect of controlling NMNAT2 levels in cortical 
neurons, we decided to overexpress the protein in primary cortical neurons 
by transfecting with a NMNAT2 plasmid. For this experiment, we co-trans-
fected cortical neurons with pmaxGFP as a reporter and pCMV-NMNAT2 at 
final concentration of 1 μg per well.  
The overexpression of NMNAT2 resulted in neurons with axons significantly 
shorter than the control by 28.58% (P value=0.008).  This is an interesting result 
considering that up to date, a plethora of studies have mainly indicated the 
protective role of Nmnat2 in neurons of the PNS but had not focused on ax-
onal growth. As NMNAT2 function in the PNS is associated with its cytoplas-
mic/axonal function, we decided to test whether the effect on axonal 
growth is indeed limited to its cytoplasmic properties.  To test this, we took 
advantage of the capacity to overexpress NMNAT1, which shares enzymatic 
activity with NMNAT2 but has a nuclear localization. Unlike its cytoplasmic 
isoform, co-transfecting cortical neurons with GPF and pCMV-NMNAT1 had 
no effect on the length of developing axons.  After finding that only NMNAT2 
has an effect on neurons we tested whether the enzymatic activity of thec-
ytoplasmic Nmnat2 was responsible for the observed phenotype. To study 
that, we transfected the cortical neurons with an enzymatically-dead 
NMNAT2 which resulted in neurons with significantly shorter 17.7% axons (P 




and may suggest the existence of a dual function mechanism. A one sample 
t-test between NMNAT2 and enzymatically-dead NMNAT2 transfected neu-
rons’ axonal growth does not indicate significant difference (P=0.0767).  
Figure 7 Overexpression of NMNATs in cortical neurons.  Developing Cortical neu-
rons were co-transfected with 1μg of pmaxGFP and 1μg of pCMV-NMNAT2 or 
pCMV-enzymatically-dead-NMNAT2 or pCMV-NMNAT1 (DIV2). The length of ax-
ons of GFP-positive neurons measured on DIV5 was 71.4%~2,764, 82.3%~4,087 and 
103%~6,334 of the control (pCMV empty vector) respectively. Data are ex-
pressed as percentage of the average length of control axons and presented as 
mean±SEM from four independent experiments. One-way ANOVA was per-
formed, P= 0,0003. Representative images of GFP-positive neurons for all condi-
tions are shown above. 
empty vector + GFP NMNAT2 + GFP 
enzymatically-dead 





























Since the loss of axonal growth could be the outcome of a decrease in cell 
viability, we decided to test neuronal death. In order to measure neuronal 
mortality, we focused on axon degeneration. As degenerated, we consid-
ered axons that had axonal swellings, appeared bead-like in part or all of 
their length. We counted alive and dead cells in all conditions and found no  
significance between the control and the experimental conditions. None of 
the overexpressed plasmid constructs had an effect on cellular mortality as 
it is shown on figure 8. In all experiments presented in this section, as control 
Healthy Neuron                     Dead Neuron 
 
Figure 8: None of the NMNATs proved to be toxic when overexpressed 
in cortical neurons.  On the pictures above we can see from left to 
right, healthy neuron with an intact axon representative of those 
measured and a dead neuron with a degenerating axon. The graph 
represents the percentage of neurons with degenerating axons as a 










we used the empty pCMV-TAG-2B vector which had no effect on axonal 
length and cell viability. 
 3.1.3 Conclusion 
Due to its essential neuronal maintenance role of NMNAT2 and its neuropro-
tective properties, understanding the regulation of NMNAT2 levels is crucial 
to unlocking its therapeutic potential (Brazill et al., 2017).  It is critical than 
neurons maintain sufficient levels of NMNAT2 as its loss is an initiating factor 
in Wallerian degeneration and has been shown to be consistent in progres-
sion of neurodegenerative diseases (Milde, Gilley and Coleman, 2013).  
Our findings that overexpression of NMNAT can lead to a decrease in axonal 
growth, can point towards a novel functional mechanism regulated by 
NMNAT2 levels during the development of neuron connectivity in the CNS. 
Interestingly, this functional role appears to depend on both enzymatic and 
non-enzymatic properties of NMNAT2, an intriguing possibility that has been 
found to be important in other models (Brazill et al., no date; Zhai et al., 2008; 
Ali et al., 2013) 
Overall, findings reported here can be interpreted in the context of those 
described for NMNAT2 in the PNS, and underline the importance for neurons 
to finetune the levels of NMNAT2 to the cell’s needs as the nervous system 
needs to adapt to many conditions and circumstances. MicroRNAs are pow-
erful regulators and thus an interesting field to focus on. 
3.2 microRNAs and Neuronal Development 
Given Nmnat2 short half-life and the presence of NMNAT2 mRNA in axons 




terminal, it is somewhat surprising that there have not been studies investi-
gating the regulation of NMNAT2 by microRNAs.  
 3.2.1 Bioinformatic Analysis 
3.2.1.1 microRNAs targeting NMNAT2 
After discovering the effect of Nmnat2 on developing neurons we decided 
to focus on the protein’s regulation by miRNAs. For that matter we performed 
a bioinformatic and bibliographic analysis to identify those miRNAs that 
could target NMNAT mRNA.  
The target prediction tool Targetscan mouse (Agarwal et al., 2015) was used 
in order to identify the putative miRNAs targeting the NMNAT2 transcript, pro-
ducing a large list of miRNA families. In brief, TargetScan is a tool which pre-
dicts biological targets of miRNAs by searching for conserved 8mer, 7mer, 
and 6mer sites that match the seed region of each miRNA (Lewis, Burge and 
Bartel, 2005) In mammals, predictions are ranked by the predicted efficacy 
of targeting which is calculated using cumulative weighted context++ 
scores (CS) of the sites (Agarwal et al., 2015). Moreover, predictions can also 
be ranked based on their probability of conserved targeting (PCT)  (Friedman 
et al., 2009).  
 We focused on the miRNA families that were conserved firstly among verte-
brates and secondly among mammals as shown in figure 9. Targetscan pre-
dicted a total of 692 microRNA families targeting NMNAT2 twelve of which 
were broadly conserved and specifically five among vertebrates and six 






To increase probabilities of identifying biologically significant miRNAs, we cu-
rated manually the list of miRNA families shown on the table below, focusing 
on expression in the nervous system and function on neuronal growth, devel-
opment and/or degeneration. That way, our initial list was narrowed down 
to four microRNAs: mmu-miR-494-3p, mmu -miR-132-3p, mmu-miR-129-3p 





Figure 9:  3’UTR of NMNAT2 and conserved sites for miRNA families. 3’UTR length is 4132 
kb. In the figure there are depicted the broadly conserved sites for miRNA families 




















3.2.1.2 Functional profile of the microRNAs 
3.2.1.2.1 miR-129-3p family and the nervous system 
Mir-129 has been shown to have the capacity to control function in axonal 
regeneration by regulating insulin-growth factor-1 in peripheral injury with its 
overexpression impairs outgrowth ability in DRG neurons. (Zhu et al., 2018). 
Both miR-129-3p and miR-129-5p have been found to be under-expressed in 
miRNA conserved 
sites 




miR-185-5p 66-72 7mer-m8 
miR-132-3p 101-107 7mer-m8 
miR-212-3p 101-107 7mer-m8 
miR-877-5p 198-204 7mer-m8 
miR-7035-5p 324-331 8mer 
miR-129-1-3p 346-353 8mer 
miR-129-2-3p 346-353 8mer 
miR-181c-5p 2591-2598 8mer 
miR-181a-5p 2591-2598 8mer 
miR-181b-5p 2591-2598 8mer 
miR-181d-5p 2591-2598 8mer 
miR-493-5p 2594-2600 7mer-m8 
miR-1197-3p 3263-3270 8mer 
miR-203-3p.1 3484-3490 7mer-m8 
miR-203-3p.2 3484-3490 7mer-1A 
miR-494-3p 3557-3564 8mer 




pilocytic astrocytoma in comparison with healthy tissue (Ho et al., 2013) mi-
croRNA-129-1 has been proposed to act as a negative regulator of Insulin-
like growth factor 2 mRNA-binding protein 3 (IGF2BP3)  and Mitogen Acti-
vated Protein Kinase 3 MAPK1 and also as a cell cycle arrest inducer in glio-
blastoma multiforme cells (GBM) cells . miR-129-3P has also been shown to 
downregulate CDK6 by potentially targeting its 3’-UTR (Ouyang et al., 2016).  
 
3.2.1.2.2 miR-181 family and the nervous system 
MiR-181 is highly expressed in the brain (Chen et al., 2004) and has been im-
plicated in apoptosis and inflammation, the regulation of lymphocyte devel-
opment and function (Ouyang, Lu, Yue and Giffard, 2012; Ouyang, Lu, Yue, 
Xu, et al., 2012; Hutchison et al., 2013; Xu et al., 2013; Zhang et al., 2013) and  
particularly, miR-181c has been shown to suppress the activation of CD4+ T 
cells (Xue et al., 2011) . MiR-181-a/b/c is downregulated in the rat brain after 
transient focal ischemia (Jeyaseelan, Lim and Armugam, 2008). 
miR-181-1 has been predicted a potential regulator in Parkinson’s disease 
mechanisms due to its interaction with known PD genes (Chandrasekaran 
and Bonchev, 2013).  It has been demonstrated that members of the miR-
181 family are involved in the regulation of microglial activation (Ye et al., 
2018). miR-181a, which is enriched in the synaptodendritic compartment of 
the nucleus accumbens, has been proved to post-transcriptionally regulate 
the glutamate receptor 2 subunit (GluA2) of AMPA-Rs. AMPA-Rs dynamics 
are crucially involved in synaptic plasticity and neuroadaptations to drugs of 
abuse and therefore miR-181a may pay play a role in addiction related neu-
roplastic changes and their therapeutic approach (Saba et al., 2012). 




plasticity associated with neuropathology in a murine model of AD  with find-
ing indicating a connection between miR-181 and proteins involve in synap-
tic plasticity and memory processing (Rodriguez-Ortiz et al., 2014). In a recent 
study showed that mir-181a interacts with ataxin’s 3′ UTR and whose expres-
sion is dysregulated in human Machado-Joseph disease (MJD) neurons and 
in other MJD cell and animal models. Moreover, overexpression of miR-
181ain mice resulted in reduction of mutATXN3 levels, aggregate counts, 
and neuronal dysfunction (Carmona et al., 2017).  
 
 
3.2.1.3.3 microRNA-132 and the nervous system 
miR-132 is one of the best characterised miRNAs in the nervous system, and 
is known for its functions in dendrite morphology and synapse function (Vo, 
Cambronne and Goodman, 2010; Siegel, Saba and Schratt, 2011; Wanet et 
al., 2012). Two of the miR-132 targets that have been studied extensively in 
dendrites are the mRNAs for Rho GTPase activator p250GAP, and transcrip-
tion factor MeCP2. miR-132 is present in the somatodendritic compartment 
and at synapses (Kye et al., 2007; Lugli et al., 2008).  MiR-132 is noticeably 
dysregulated in major neurodevelopmental, psychiatric, and neurodegen-
erative diseases such as Alzheimer’s Disease, Schizophrenia and Autism 
Spectrum Disorder (Mellios and Sur, 2012; Pichler et al., 2017).   
In AD brains, miR132-3p levels are decreased in neurons enriched with hy-
per-phosphorylated Tau (Lau et al., 2013). Various genes involved in Tau 
network, including the transcription factor (TF) FOXO1a, were identified as 




miR132/212 cluster results in rise of Tau phosphorylation and aggregation. 
In an AD mouse model, miR132 treatment rescued memory deficits (Wanet 
et al., 2012).  
In new-born hippocampal neurons miR-132 plays an important role by influ-
encing dendritic branching and synaptic integration (Magill et al., 2010; 
Luikart et al., 2011). Growth factors such as brain-derived neurotrophic factor 
(BDNF) are known to interfere with miRNA expression and function. For ex-
ample, BDNF can induce the expression of miR-132 and co-transcribed miR-
212 (Remenyi et al., 2010). Hippocampal miR-132 mediates stress-induced 
cognitive deficits by suppressing acetylcholinesterase (Haramati et al., 
2011). miR-132 has been implicated in neuropathic pain after chronic con-
striction injury (CCI) (Arai et al., 2013). On a similar note, spinal cord miR-132 
has been proposed as a mediator of neuropathic pain following spared 
nerve injury (SNI) (Zhang et al., 2015). 
Overexpression of the miR132 precursor in primary cortical neurons increases 
neurite sprouting  in comparison to cells transfected with pmaxGFP 
alone  (Vo et al., 2005). It has also been shown that neurons secrete miR-132-
containing exosomes to regulate brain vascular integrity, a finding that con-
tributes to the role of miR-132 of miR-132 in neural development and function 
(Xu et al., 2017). In vivo inhibition of miR-132 function in visual cortex resulted 
in increased levels of spine inhibitor p250GAP and reduced dendritic spine 
density and immature morphology (Mellios et al., 2011). On the other hand, 
in vivo upregulation of miR-132 expression promoted spine maturation 
(Tognini et al., 2011). Both of these manipulations affected ocular domi-
nance plasticity and thus suggest that balanced levels of miR-132 are re-
quired for brain plasticity, and that too high or too low levels of miR-132 ex-
pression can result in precocious or delayed cortical maturation. Multiple 




in an experience-dependent manner (Nudelman et al., 2009). miR-132 re-
presses Rasa1 mRNA (a Ras GTPase activator), in a mechanism that operates 
locally within the axon. miR-132 levels in DRGs peaked in the period of max-
imum axon growth in vivo which suggests it has a role as a developmental 
timer. (Hancock et al., 2014).  
 
3.2.1.2.4 microRNA-494 and the nervous system 
Mir-494, a broadly conserved family among mammals microRNA, is not par-
ticularly studied in the nervous system yet. Xiong et al. showed that miR-494, 
which is abundantly present in substantia nigra pars compacta (SNpc), tar-
gets DJ-1. Gain of miR-494 function led to decreased DJ-1 protein levels and 
caused increased oxidative stress as well as loss of dopaminergic (DA) neu-
rons in both in vitro and in vivo studies, thus confirming miR-mediated regu-
lation of DJ-1 in PD pathogenesis (Xiong et al., 2014). MiR-494-3p has been 
found to be a modulator of the progression of in vitro and in vivo PD models 
by targeting sirtuin 3 (SRT3). It has been shown to be upregulated in ma-
caques suffering from bovine spongiform encephalopathies-infected ma-
caques compared to non-infected animals (Saba et al., 2008). 
A recent study showed that mir-494 interacts with ataxin’s 3′ UTR, whose ex-
pression is dysregulated in human Machado-Joseph disease (MJD) neurons 
and in other MJD cell and animal models and that the overexpression of miR-
494in mice resulted in reduction of mutATXN3 levels, aggregate counts, and 
neuronal dysfunction (Carmona et al., 2017). MiR-494-3p is a negative regu-
lator of semaphorin 3A (SEMA3A) and other targets associated with axonal 




were found to be dysregulated which  affects neurite network mainte-
nance. In particular a downregulation of  miR-494-3p was identified and it 
was shown that by restoring miR-494-3p levels through expression of an engi-
neered miRNA mimic Sema3A levels in motor neurons (MN) can be down-
regulated resulting in an increase of MN survival in vitro (Varcianna et al., 
2019).  
3.2.2 Conclusion 
Combining the bioinformatic tools and manual curation allowed us to select 
four microRNAs targeting NMNAT2 with a potential role in the nervous system 
and effect on Nmnat2 levels. Given that Nmnat2 is a critical protein for neu-
ronal survival and maintenance, we proceeded to investigate the role of 
these four microRNAs in axon growth, 
 
3.3 Analysis of selected microRNAs and their role in axon develop-
ment 
3.3.1 Functional Analysis of microRNAs in cortical neurons 
After the identification of the four miRNAs by bioinformatic tools, manual cu-
ration on NCBI and extensive bibliographic review, we proceeded to test 




3.3.1.1 miR-129-3p  
Following the prediction of miR-129-3p as conserved amongst vertebrates 
microRNA that targets NMNAT2 we decided to test its putative role in neu-
ronal development and axonal outgrowth in vitro. Consequently, in order to 
assess the effect of increasing miR-129-1-3p levels in developing axons, cor-
tical neurons were co-transfected with pmaxGFP and miR-129-1-3p mimic or 
a non-targeting oligonucleotide control (mimic negative control) at DIV2 
and axon length was measured on DIV5. As it is shown in figure 10, overex-
pression of miR-129-1-3p leads to axonal shortening of 21% compared to 
























pmaxGFP + mimic control 
pmaxGFP + miR-129-1-3p 
 
Figure 10. miR-129-1-3p induces decrease of axonal length in cortical neurons. 
Developing Cortical neurons were transfected with miR-129-1-3p mimic (DIV2), 
the length of axons of GFP-positive neurons measured on DIV5 was 79%~4,28 the 
control (both at 20mM). Neurons were co-transfected with GFP for visualisation 
of transfection. Control neurons were transfected with non-targeting oligonucle-
otides. Data are expressed as percentage of the average length of control ax-
ons and presented as mean±SEM from five independent experiments. One sam-
ple t-test. P= 0,0162. Representative images of GFP-positive neurons for both con-





transfected at 20 nM final concentration. We followed the one sample t-test 
statistical analysis and our findings have a p-value of 0,0162<0.05 which dic-
tates that our results are statistically significant. 
3.3.1.2 microRNA-181 
Similarly, after predicting miR-181-a-5p as conserved among vertebrates mi-
croRNA that targets NMNAT2 we decided to test its putative role in neuronal 
development and axonal outgrowth in vitro. In order to assess the effect of 
increasing miR-181-a-5p levels in developing axons, cortical neurons were 
co-transfected with pmaxGFP and the miR-181-a-5p mimic or a non-target-
ing oligonucleotide control (mimic negative control) both at final concen-
tration 20 nM at DIV2 and axon length was measured on DIV5. As it is shown 
in figure 9. overexpression of miR-181-a-5p has no significant effect on the 
outgrowth of cortical neurons. The average axon length of the experimental 
condition was by 15.78% shorter but the decrease in axonal length was not 








Mir-132-3p was likewise predicted as a conserved amongst vertebrates’ 
miRNA targeting NMNAT2. To test its effect when overexpressed in cortical 
neurons primary cortical cultures were co-transfected with pmaxGFP and 
the miR-132-3p mimic  
GFP + miR-181a-5p mimic 
GFP + mimic control 
 
FIGURE 9: miR-181a-5p does not have an effect on axonal length of cortical 
neurons. Developing Cortical neurons were transfected with miR-181a-5p 
mimic (DIV2), the length of axons of GFP-positive neurons measured on DIV5 
was 84.22%~6,562 of the control (both at 20mM). Neurons were co-transfected 
with GFP for visualisation of transfection. Control neurons were transfected with 
non-targeting oligonucleotides. Data are expressed as percentage of the av-
erage length of control axons and presented as mean±SEM from five inde-
pendent experiments. One sample t-test. P=0,0902. Representative images of 



























or a non-targeting oligonucleotide control (mimic negative control) both at 
final concentration 20 nM at DIV2 and axon length was measured on DIV5. 
As it is depicted in figure 10 overexpression of miR-132-3p has no significant 
effect on axonal outgrowth. The average axon length of the experimental 
condition was by 5.26% shorter. We performed a one sample t-test and got 
a P value of 0.2542>0.05. 
Figure 10: miR-132-3p has no significant effect in axonal length of cortical 
neurons. Developing Cortical neurons were transfected with miR-132-3p 
mimic (DIV2), the length of axons of GFP-positive neurons measured on DIV5 
was 88.21%~9,762 of the control (both at 20mM). Neurons were co-trans-
fected with GFP for visualisation of transfection. Control neurons were trans-
fected with non-targeting oligonucleotides. Data are expressed as percent-
age of the average length of control axons and presented as mean±SEM 
from five independent experiments. One sample t-test. P=0.2542. Repre-






























3.3.1.4   miR-494-3p 
Mir-494-3p was predicted as conserved amongst mammalian miRNA target-
ing NMNAT2. To test its effect when overexpressed in cortical neurons primary 
cortical cultures were co-transfected with pmaxGFP and the miR-494-3p 
mimic or a non-targeting oligonucleotide control (mimic negative control) 
both at final concentration 20 nM at DIV2 and axon length was measured 
as on DIV5. As it is depicted in figure 11 overexpression of miR-494-3p has no 
significant effect on axonal outgrowth. The average axon length of the ex-
perimental condition was by 5.24% shorter but the results were not significant. 






























Our results show that most of the miRNAs we tested had no effect on axonal 
growth. However, overexpression of miR-129-1-3p resulted in significantly 
shorter axons and thus suggests that regulation by this miRNA may have an 
effect on axon development. Future work could include functional rescues 
with NMNAT2 overexpression to test whether the miRNA has indeed an effect 
that is mediated by NMNAT2. However, the effect may not be mediated by 
the targeting of NMNAT2 only or exclusively. In order to investigate this further 
we decided to test the expression of endogenous NMNAT2 mRNA levels in 
cells transfected with two of the microRNAs, miR-129-1-3p (which phenotyp-
ically had an effect) and miR-181a-5p.  
3.3.2 Expression of NMNAT2 in N2A cells after overexpression of miRNAs 
Following the functional analysis of the four miRNAs, where miR-129-1-3p 
showed to have a shortening effect in developing axons when overex-
pressed, we decided to assess the NMNAT2 transcript levels in cortical neu-
rons transfected with miR-129-1-3p and miR-181a-5p which appeared to 
have no effect on developing neurons. In order to do that, we used Neuro2A 
FIGURE 11 miR-494-3p has no significant effect in axonal length of cortical neu-
rons. Developing Cortical neurons were transfected with miR-494-3p mimic 
(DIV2), the length of axons of GFP-positive neurons measured on DIV5 was 
97.70%~9,678 of the control (both at 20mM). Neurons were co-transfected with 
GFP for visualisation of transfection. Control neurons were transfected with non-
targeting oligonucleotides. Data are expressed as percentage of the average 
length of control axons and presented as mean±SEM from five independent 
experiments. One sample t-test. P=0,8188. Representative images of GFP-posi-





cells as they have significantly higher transfection efficiency compared to 
primary cortical neurons, making them an ideal model to test the effects of 
miRNA mimics in NMNAT2 mRNA levels, which would otherwise be extremely 
challenging.  In order to identify these microRNAs effect on NMNAT2 mRNA 
levels we quantified the NMNAT2 transcript’s levels in N2A cells where either 
miR-129-1-3p or miR-181a-5p had been overexpressed.  
The cells were transfected with the mimic control or the miRNA mimics at 
50nM final concentration,24h after plating and the NMNAT2 mRNA levels 
were measured by Real Time qPCR 48h and 72h after transfection. Relative 
expression at each time point was calculated following the comparative 
ΔΔCt method as shown in the diagrams below. Regarding miR-129-1-3p 
transfected cells, fold change was measured 0.406~0,194 after 24 hours, 
1,131~0,136 after 48 hours and 0,746 after 72 hours. In miR-181a-5p trans-
fected cells, fold change was measured 1,130~0,351 after 48 hours and 0,900 
after 72 hours. The results suggest that the expression levels begin to alter 3 
days after transfection as we begin to see minor differences compared to 
the control. More experiments need to be conducted regarding that at the 
72h time point, as only one experiment was performed per condition (hence 
the relatively high variability) and because the 48h time point proved to be 
rather early for any safe conclusions. The error bar on the miR-181a-5p on the 




                                                                                          
 
Conclusion 
As we showed in the previous chapter, mir-129-1-3p overexpression in pri-
mary cortical neurons resulted in significantly shorter axons. qPCR results in-
dicate that miR-129-1-3p, which showed the strongest effect among the two 
miRNAs we amplified, provide early confirmation that this miRNA may in-
deed target NMNAT2. More experiments an on later time points should be 
performed in order to acquire a clearer picture and to reach further conclu-
sions. 
Figure 12: Endogenous NMNAT2 after miRNAs overexpression (A) Nmnat2 transcript was quan-
tified by RT-qPCR in N2A cultures 48 (n=3) and 72h(n=1) after transfection with miR-129-1-3p 
mimic (50nM). The graph represents Nmnat2 expression levels relative to that of Control Mimic 
transfected neurons. (B) Nmnat2 transcript was quantified by RT-qPCR in N2A cultures 48 (n=2) 
and 72h(n=1) after transfection with miR-181a-5p mimic (50nM). The graph represents Nmnat2 
expression levels relative to that of Control Mimic transfected neurons.  Data is expressed as 
fold change to control from each time point, mean±SEM of n independent experiments (see 

























































Chapter 4: Discussion  
NMNAT2 catalyses the synthesis of NAD from NMN and ATP and is particularly 
important because its transcript is expressed predominately in the brain 
(Sood et al., 2001; Raffaelli et al., 2002; Yalowitz et al., 2004). Axons require a 
constant supply of the labile axon survival factor Nmnat2 to avoid sponta-
neous axon degeneration while depletion of this isoform causes a primary 
axonal phenotype either in vitro or in vivo (Conforti et al., 2011; Gilley et al., 
2013).  
Supporting a protective role of Nmnat2 in axon survival, strong overexpres-
sion of Nmnat2 in PNS neurons, has been shown to delay Wallerian degen-
eration in vitro, and this protective effect is dependent on its enzymatic ac-
tivity (Gilley and Coleman, 2010; Yan et al., 2010). Nmnat2 role in central 
nervous system has been significantly less studied and for that reason we 
decided to investigate NMNAT2 overexpression in primary cortical cultures. 
NMNAT2 mRNA has been detected in axons and given the protein’s short 
half-life, it is reasonable to conclude that regulation must be tightly fine-
tuned in order to control its levels. Part of our work attempted to shed light in 
Nmnat2 regulation by microRNAs in cortical neurons, which surprisingly had 
not been investigated yet. For that matter, we conducted a bioinformatic 
and bibliographic research and identified four strong miRNA candidates 
that putatively target NMNAT2 transcripts and repress their expression. 
Overexpression of NMNAT2 in primary cortical neurons, led to significantly 
shorter axons. Up to date data have shown that the overexpression of 
NMNAT2 in PNS neurons has protective role but its effect on axonal length 
had not been investigated. We proceeded to overexpress the nuclear iso-




on axonal length. overexpression of the enzymatically-dead NMNAT2 had a 
shortening effect on axons but not as robust as that of wild type NMNAT2. 
These findings indicate that the effect of Nmnat2 on axon growth may not 
rely exclusively on NMNAT2 enzyme activity. As mentioned in the introduc-
tion, Nmnat2 apart from its enzymatic activity it also acts as a chaperone. 
Indeed, an alternative theory suggests that NMNAT provide protection via 
an enzyme-independent function, leading to the hypothesis that NMNAT 
mediated neuroprotection is chaperone-dependent. For example, it has 
been shown that Nmnat2’s enzyme activity is dispensable for relieving the 
toxic phosphorylated tau burden in a model of fronto-temporal dementia 
and parkinsonism 17 (FTDP-17), but Nmnat2 forms a complex with HSP90 
chaperone, possibly to promote refolding of toxic tau (Ali et al., 2016).  
In any case, the study of Nmnat2 regulation is of great importance as it is a 
protein associated with various neurodegenerative conditions. Naturally, we 
focused on Nmnat2 potential regulation by miRNAs which regulate gene ex-
pression by mRNA degradation or translational repression.  
After the prediction of four putative regulators, miR-129-1-3p, miR-181a-5p, 
miR-132-3p and miR-494-3p through bioinformatic analysis and manual cu-
ration, we proceeded on functional studies on neuronal cultures. All four miR-
NAs were overexpressed in primary cortical neurons. Neurons transfected 
with miR-129-1-3p showed significant axonal shortening which is an indica-
tion that the microRNA may have a regulatory effect on Nmnat2.  
Given that NMNAT2 when overexpressed cause decrease in axon growth 
the fact that we acquire similar results from the overexpression of miR-129-1-
3p, a predicted to target NMNAT2 microRNA, appears contradictory. There 
are though some possible explanations behind this contradiction. There is a 




targets other 437 genes according to Targetscan (Agarwal et al., 2015) and 
thus, our phenotype may appear because of the miRNA’s interaction of an-
other or other genes.  
Our contradictory result can also point at the fact that NMNAT2 levels, as we 
previously underlined, need to be tightly controlled and any change of its 
essential levels may lead to axonal impairments. This may explain why such 
a fundamental for axonal function protein has developed to be delivered 
to the axon and have such a short half-life. When a protein is so tightly regu-
lated, any change in its levels, increase or decrease, would lead to harmful 
outcomes for the cell.  
In order to investigate whether our phenotype was related with miRNA re-
pression of Nmnat2, we measured NMNAT2 mRNA levels in Neuroblas-
toma2A cells, where the microRNAs had been overexpressed, by qPCR. 
qPCR results indicate that miR-129-1-3p targets NMNAT2 and represses its ex-
pression. The effect can be observed after 72h of transfection so more ex-
periments on this and later time points could help us acquire a better view.  
Future experiments of functional rescues with NMNAT2 overexpression could 
test whether the miRNA has indeed an effect on the specific protein and the 
phenotype is because of its repression exclusively or partially. 
Regarding NMNAT2’s chaperone activity, a big question that needs to be 
addressed is which are these proteins that NMNAT2 “chaperones” under 
physiological conditions.  Genome editing approaches in mice could be 
tried to test NMNAT2’s chaperone activity and to investigate if it is essential 
in the brain. 
The regulation of NMNAT2 seems to be extremely fine-tuned due to its labile 




patterns. It would be informative to perform experiments of inhibition of the 
endogenous miRNAs and especially miR-129-1-3p which seems to have an 
effect on axon growth. Since Nmnat2 might be locally post-transcriptionally 
modified and/or translated the use of compartmentalised cultures in our 
studies of regulation, would provide more information regarding the mRNA 
and protein spatiotemporal distribution across development. Moreover, we 
could compare through qPCR, NMNAT2 mRNA from somata and axons of 
cortical to investigate whether the levels differentiate between the two sub-
cellular compartments after transfection with miRNAs.  
The levels of the protein per se in cortical neurons, could be measured by 
luciferase assay and that could be done also separately in somata and ax-
ons to check whether there is a difference in the expression. This is something 
we were interested in doing but unfortunately antibodies available for 
Nmnat2 are not entirely reliable (Coleman lab, personal communication). 
MicroRNAs, depending on the specific context can have either protective 
or disease-promoting effects and their manipulation may offer novel thera-
peutic opportunities for neurodevelopmental disorders of complex genetic 
origins. Furthermore, the manipulation of NMNAT2 by miRNAs, which has 
been associated with cognition and major condition such as Parkinson’s, Alz-
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